Upregulated PXN expression was linked to poor prognosis and OS in many cancers, including GBM, HNSC, acute myeloid leukemia, LGG, LIHC, LUSC, mesothelioma (MESO), ovarian cancer, pancreatic adenocarcinoma (PAAD), and skin cutaneous melanoma (SKCM) (Figure 2A). This evidence concerns the gene PXN and ovarian cancer.